Impact of Monosodium Glutamate on 68GA-PSMA-11, PET Imaging Biodistribution in Patients With Prostate Cancer
Status:
Completed
Trial end date:
2020-05-06
Target enrollment:
Participant gender:
Summary
This phase I trial studies the impact of monosodium glutamate (MSG) on 68GA-PSMA-11 PET/CT in
decreasing the salivary glands uptake in patients with prostate cancer. Prostate specific
membrane antigen (PSMA) is a molecule that is overexpressed by the prostate cancer cells.
68GA-PSMA-11 is an imaging radioactive drug that can target this molecule in tissues for
imaging and therapy of prostate cancer. Food substances, such as monosodium glutamate, may
reduce salivary gland uptake of 68GA-PSMA-11. Ultimately, giving MSG may reduce potential
harm and injury to the salivary glands in patients with prostate cancer treated with
PSMA-targeted molecular radiotherapy.